US20010036952A1 - Small molecule pipecolic acid derivative hair growth compositions and uses - Google Patents
Small molecule pipecolic acid derivative hair growth compositions and uses Download PDFInfo
- Publication number
- US20010036952A1 US20010036952A1 US09/784,174 US78417401A US2001036952A1 US 20010036952 A1 US20010036952 A1 US 20010036952A1 US 78417401 A US78417401 A US 78417401A US 2001036952 A1 US2001036952 A1 US 2001036952A1
- Authority
- US
- United States
- Prior art keywords
- straight
- branched chain
- alkyl
- alkenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C(=*)C(=O)N(*)C([K])C(=O)*CC([2H])B Chemical compound *C(=*)C(=O)N(*)C([K])C(=O)*CC([2H])B 0.000 description 16
- PEKUPEYPAFWJMO-HHMJLCMQSA-N [H][C@@]1(C(=O)OB)CCCN1C(=O)C([2H])=O Chemical compound [H][C@@]1(C(=O)OB)CCCN1C(=O)C([2H])=O PEKUPEYPAFWJMO-HHMJLCMQSA-N 0.000 description 4
- SZBXUAFITADSQQ-UHFFFAOYSA-N O=C(OCCCC1=CN=CC=C1)C1CCCN1C(=S)NC1CCCCC1 Chemical compound O=C(OCCCC1=CN=CC=C1)C1CCCN1C(=S)NC1CCCCC1 SZBXUAFITADSQQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Definitions
- This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, small molecule pipecolic acid derivatives.
- Hair loss occurs in a variety of situations. These situations include male pattern alopecia, alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and systematic disorders such as nutritional disorders and internal secretion disorders.
- the mechanisms causing hair loss are very complicated, but in some instances can be attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities.
- the immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner.
- alopecia areata One form of hair loss, alopecia areata, is known to be associated with autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss.
- the hair growth stimulating effects of FK506 have been the subject of an international patent filing covering FK506 and structures related thereto for hair growth stimulation (Honbo et al., EP 0 423 714 A2).
- Honbo et al. discloses the use of relatively large tricyclic compounds, known for their immunosuppressive effects, as hair revitalizing agents.
- immunosuppressive compounds by definition suppress the immune system and also exhibit other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds.
- the present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a low molecular weight, small molecule pipecolic acid derivative.
- the present invention further relates to a pharmaceutical composition which comprises:
- the pipecolic acid derivatives used in the inventive methods and pharmaceutical ccmpositions include immunosuppressive and non-immunosuppressive compounds having an affinity for FKBP-type immunophilins, particularly FKBP12.
- immunosuppressive and non-immunosuppressive compounds having an affinity for FKBP-type immunophilins, particularly FKBP12.
- Non-immunosuppressive compounds do not exert any significant immunosuppressive activity.
- FIG. 1 is a photograph of mice treated with a vehicle after six weeks.
- FIG. 1 shows that less than 3% of the shaved area is covered with new hair growth when the vehicle (control) is administered.
- FIG. 2 is a photograph of mice treated with 10 ⁇ M of GPI 1044 after six weeks.
- FIG. 2 shows that 90% of the shaved area is covered with new hair growth when GPI 1044 is administered.
- FIG. 3 is a bar graph plotting the hair growth scores of unshaven animals and shaven animals treated with a vehicle, GPI 1044 (1 ⁇ M, 3 ⁇ M and 10 ⁇ M), and related pipecolic acid derivative neuroimmunophilin FKBP ligands GPI 1116 (1 ⁇ M and 10 ⁇ M) and GPI 1102 (1 ⁇ M and 3 ⁇ M).
- FIG. 4 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and related neuroimmunophilin FKBP ligands 14 days after treatment with each identified compound.
- FIG. 4 demonstrates the remarkable early hair growth promoted by neuroimmunophilin FKBP ligands.
- Alopecia refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness), toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania.
- Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen phase during which the follicles are detached from the dermal papillae, and the hairs fall out.
- Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs.
- GPI 1044 refers to Compound 4 .
- GPI 1102 refers to 4-phenyl-1-(3-phenylpropyl) butyl 1- (3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate.
- GPI 1116 refers to 1-phenethyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate.
- “Isomers” refer to different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. “Diastereoisomers” are stereoisomers which are not mirror images of each other. “Racemic mixture” means a mixture containing equal parts of individual enantiomers. “Non-racemic mixture” is a mixture containing unequal parts of individual enantiomers or stereoisomers.
- “Pharmaceutically acceptable salt, ester, or solvate” refers to a salt, ester, or solvate of a subject compound which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable.
- a salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesul
- base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth.
- the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; aralkyl halides, such as benzyl and phenethyl bromides; and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides
- dialkyl sulfates such as dimethyl, diethyl, dibutyl, and diamyl sulfates
- Palm cycle refers to the life cycle of hair follicles, and includes three phases:
- telogen phase hair is uniform in diameter with a slightly bulbous, non-pigmented root.
- anagen phase hair has a large colored bulb at its root.
- “Promoting hair growth” refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
- Treating alopecia refers to:
- Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep in the dermis.
- Vellus hair is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type.
- the present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative.
- the inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising:
- the pipecolic acid derivatives used in the methods and pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins, such as FKBP12.
- FKBP-type immunophilins such as FKBP12.
- FKBP12 FKBP12
- rotamase inhibiting compounds may be immunosuppressive or non-immunosuppressive. Examples of useful compounds are set forth below.
- An exemplary pipecolic acid derivative is a compound of formula I
- m is 0-3;
- A is CH 2 , O, NH, or N—(C 1 -C 4 alkyl);
- B and D are independently Ar, C 5 -C 7 cycloalkyl substituted C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkenyl substituted C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl, or Ar substituted C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl, wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO 2 in chemically reasonable substitution patterns, or
- Q is hydrogen, C 1 -C 6 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl
- T is Ar or C 5 -C 7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4 alkyl), O—(C 2 -C 4 alkenyl), and carbonyl;
- Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatom(s) independently selected from the group consisting of oxygen, nitrogen and sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF 3 , trifluoromethoxy, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, O—(C 1 -C 4 straight or branched chain alkyl), O—(C 2 -C 4 straight or branched chain alkenyl), O-benzyl, O
- L is either hydrogen or U;
- M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;
- U is hydrogen, O—(C 1 -C 4 straight or branched chain alkyl), O—(C 2 -C 4 straight or branched chain alkenyl), C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, (C 1 -C 4 alkyl or C 2 -C 4 alkenyl) —Ar, or Ar;
- J is hydrogen, C 1 or C 2 alkyl, or benzyl
- K is C 1 -C 4 straight or branched chain alkyl, benzyl or cyclohexylmethyl
- J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 ;
- said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
- A is O, NH, or N—(C 1 -C 4 alkyl)
- B is hydrogen, CHL-Ar, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, Ar substituted C 1 -C 6 alkyl or C 2 -C 6 alkenyl, or
- L and Q are independently hydrogen, C 1 -C 6 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl;
- T is Ar or C 5 -C 7 cyclohexyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C 1 -C 4 alkyl), O—(C 2 -C 4 alkenyl), and carbonyl;
- Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF 3 , C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, O—(C 1 -C 4 straight or branched chain alkyl), O—(C 2 -C 4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.
- D is hydrogen or U;
- E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;
- U is hydrogen, O—(C 1 -C 4 straight or branched chain alkyl), O—(C 2 -C 4 straight or branched chain alkenyl), C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 -cycloalkyl, C 5 -C 7 cycloalkenyl substituted with C 2 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C 1 -C 4 alkyl or C 2 -C 4 alkenyl)-Ar, or Ar;
- J is hydrogen, C 1 or C 2 alkyl, or benzyl
- K is C 1 -C 4 straight or branched chain alkyl, benzyl or cyclohexylethyl
- J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO 2 .
- a preferred pipecolic acid derivative is a compound of Formula III
- n 2;
- D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl
- B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl)butyl;
- D is phenyl
- B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;
- D is methoxy
- B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;
- D is 3,4,5-trimethoxyphenyl
- B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3- (3-indolyl)propyl, or 4- (4 -methoxyphenyl)butyl.
- the pipecolic acid derivative may also be a compound of formula IV
- V is C, N, or S
- J and K taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO 2 , N, NH, and NR;
- R is either C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 1 -C 9 cycloakyl, C 5 -C 7 cycloalkenyl, or Ar 1 , wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar 2 ;
- Ar 1 and Ar 2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;
- A, B, D, L, M, and m are as defined in Formula I above;
- said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
- All the compounds of Formulas I-IV possess asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers.
- the individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving the compounds of Formulas I-IV. It is understood that the compounds of Formulas I-IV encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers.
- S-stereoisomers are used in the pharmaceutical compositions and methods of the present invention.
- the compounds used in the inventive methods and pharmaceutical compositions have an affinity for the FK506 binding protein, particularly FKBP12.
- the inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.
- a plastic cuvette In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various concentrations in dimethyl sulfoxide.
- the reaction is initiated by the addition of 5 mL of substrate (succinyl-Ala—Phe—Pro—Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).
- the compounds used in the inventive methods and pharmaceutical compositions must readily affect the targeted areas.
- the compounds are preferably administered topically to the skin.
- the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60 , cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg.
- the specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.
- in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
- the compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the drug combination.
- Experiment A C57 black 6 mice were used to demonstrate the hair revitalIzing properties of pipecolic acid derivative GPI 1044 (compound 4 ), as well as related pipecolic acid derivative neuroimmunophilin FKBP ligands GPI 1102 and GPI 1116 .
- C57 black 6 mice approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlaying dermal layers.
- the animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS. 1 and 2, four animals were treated by topical administration with 20% propylene glycol vehicle (FIG.
- Experiment B C57 Black 6 mice were used to demonstrate the hair revitalizing properties of neuroimmunophilin FKBP ligands.
- GPI 1116 or 1206 a neuroimmunophilin FKBP ligand
- the animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area).
- FIG. 4 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with one of the low molecular weight, small molecule, neuroimmunophilin FKBP ligands exhibited dramatic hair growth.
- a lotion comprising the following composition may be prepared. (%) 95% Ethanol 80.0 a pipecolic acid derivative as defined above 10.0 ⁇ -Tocopherol acetate 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s.
- 5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
- a lotion comprising the following composition shown may be prepared. (%) 95% Ethanol 80.0 a pipecolic acid derivative as defined above 0.005 Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil Purified water 19.0 Perfume and dye q.s.
- the lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
- An emulsion may be prepared from A phase and B phase having the following compositions. (%) (A phase) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monooleate 1.0 a pipecolic acid derivative as defined above 0.01 (B phase) Glycerine 10.0 Purified water 69.0 Perfume, dye, and preservative q.s.
- the A phase and the B phase are respectively heated and melted and maintained at 80° c. Both phases are then mixed and cooled under stirring to normal temperature to obtain an emulsion.
- the emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia.
- a cream may be prepared from A phase and B phase having the following compositions.
- (%) (A Phase) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3
- B Phase a pipecolic acid derivative as defined above 0.8 Glycerine 7.0 Dipropylene glycol 20.0
- Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0.005 Purified water 44.895
- the A phase is heated and melted, and maintained at 70° C.
- the B phase is added into the A phase and the mixture is stirred to obtain an emulsion.
- the emulsion is then cooled to obtain a cream.
- the cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
- a liquid comprising the following composition may be prepared. (%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 a pipecolic acid derivative as defined above 0.001 Propylene glycol 5.0 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q.s.
- the liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
- a shampoo comprising the following composition may be prepared. (%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 Polyethylene glycol 5.0 a pipecolic acid derivative as defined above 5.0 Ethanol 2.0 Perfume 0.3 Purified water 69.7
- the shampoo may be used on the scalp once or twice per day.
- a patient is suffering from alopecia senilis.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from male pattern alopecia.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from alopecia areata.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by skin lesions.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by tumors.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by a systematic disorder, such as a nutritional disorder or an internal secretion disorder.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by chemotherapy.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by radiation.
- a pipecolic acid derivative, or a pharmaceutical composition comprising the same may be administered to the patient. Increased hair growth is expected to occur following treatment.
Abstract
This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using pipecolic acid derivatives.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 08/869,426, filed on Jun. 4, 1997, the entire contents of which are herein incorporated by reference.
- 1. Field of Invention
- This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, small molecule pipecolic acid derivatives.
- 2. Description of Related Art
- Hair loss occurs in a variety of situations. These situations include male pattern alopecia, alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and systematic disorders such as nutritional disorders and internal secretion disorders. The mechanisms causing hair loss are very complicated, but in some instances can be attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities.
- The immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner. One form of hair loss, alopecia areata, is known to be associated with autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss. The hair growth stimulating effects of FK506 have been the subject of an international patent filing covering FK506 and structures related thereto for hair growth stimulation (Honbo et al.,
EP 0 423 714 A2). Honbo et al. discloses the use of relatively large tricyclic compounds, known for their immunosuppressive effects, as hair revitalizing agents. - The hair growth and revitalization effects of FK506 and related agents are disclosed in many U.S. patents (Goulet et al., U.S. Pat. No. 5,258,389; Luly et al., U.S. Pat. No. 5,457,111; Goulet et al., U.S. Pat. No. 5,532,248; Goulet et al., U.S. Pat. No. 5,189,042; and Ok et al., U.S. Pat. No. 5,208,241; Rupprecht et al., U.S. Pat. No. 5,284,840; Organ et al., U.S. Pat. No. 5,284,877). These patents claim FK506 related compounds. Although they do not claim methods of hair revitalization, they disclose the known use of FK506 for effecting hair growth. Similar to FK506 (and the claimed variations in the Honbo et al. patent), the compounds claimed in these patents are relatively large. Further, the cited patents relate to immunomodulatory compounds for use in autoimmune related diseases, for which FK506's efficacy is well known.
- Other U.S. patents disclose the use of cyclosporin and related compounds for hair revitalization (Hauer et al., U.S. Pat. No. 5,342,625; Eberle, U.S. Pat. No. 5,284,826; Hewitt et al., U.S. Pat. No. 4,996,193). These patents also relate to compounds useful for treating autoimmune diseases and cite the known use of cyclosporin and related immunosuppressive compounds for hair growth.
- However, immunosuppressive compounds by definition suppress the immune system and also exhibit other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds.
- Hamilton and Steiner disclose in U.S. Pat. No. 5,614,547 novel pyrrolidine carboxylate compounds which bind to the immunophilin FKBP12 and stimulate nerve growth, but which lack immunosuppressive effects. Unexpectedly, it has been discovered that these non-immunosuppressant compounds promote hair growth with an efficacy similar to FK506. Yet their novel small molecule structure and non-immunosuppressive properties differentiate them from FK506 and related immunosuppressive compounds found in the prior art.
- The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a low molecular weight, small molecule pipecolic acid derivative.
- The present invention further relates to a pharmaceutical composition which comprises:
- (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal; and
- (ii) a pharmaceutically acceptable carrier.
- The pipecolic acid derivatives used in the inventive methods and pharmaceutical ccmpositions include immunosuppressive and non-immunosuppressive compounds having an affinity for FKBP-type immunophilins, particularly FKBP12. Non-immunosuppressive compounds, as their name suggests, do not exert any significant immunosuppressive activity.
- FIG. 1 is a photograph of mice treated with a vehicle after six weeks. FIG. 1 shows that less than 3% of the shaved area is covered with new hair growth when the vehicle (control) is administered.
- FIG. 2 is a photograph of mice treated with 10 μM of
GPI 1044 after six weeks. FIG. 2 shows that 90% of the shaved area is covered with new hair growth whenGPI 1044 is administered. - FIG. 3 is a bar graph plotting the hair growth scores of unshaven animals and shaven animals treated with a vehicle, GPI1044 (1 μM, 3 μM and 10 μM), and related pipecolic acid derivative neuroimmunophilin FKBP ligands GPI 1116 (1 μM and 10 μM) and GPI 1102 (1 μM and 3 μM).
- FIG. 4 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and related neuroimmunophilin FKBP ligands 14 days after treatment with each identified compound. FIG. 4 demonstrates the remarkable early hair growth promoted by neuroimmunophilin FKBP ligands.
- “Alopecia” refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness), toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania. Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen phase during which the follicles are detached from the dermal papillae, and the hairs fall out. Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs.
- “
GPI 1044” refers toCompound 4. - “
GPI 1102” refers to 4-phenyl-1-(3-phenylpropyl) butyl 1- (3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate. - “
GPI 1116” refers to 1-phenethyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate. -
- “Isomers” refer to different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. “Diastereoisomers” are stereoisomers which are not mirror images of each other. “Racemic mixture” means a mixture containing equal parts of individual enantiomers. “Non-racemic mixture” is a mixture containing unequal parts of individual enantiomers or stereoisomers.
- “Pharmaceutically acceptable salt, ester, or solvate” refers to a salt, ester, or solvate of a subject compound which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable. A salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, naphthylate, 2-naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate and undecanoate. Examples of base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; aralkyl halides, such as benzyl and phenethyl bromides; and others. Water or oil-soluble or dispersible products are thereby obtained.
- “Pilar cycle” refers to the life cycle of hair follicles, and includes three phases:
- (1) the anagen phase, the period of active hair growth which, insofar as scalp hair is concerned, lasts about three to five years;
- (2) the catagen phase, the period when growth stops and the follicle atrophies which, insofar as scalp hair is concerned, lasts about one to two weeks; and
- (3) the telogen phase, the rest period when hair progressively separates and finally falls out which, insofar as scalp hair is concerned, lasts about three to four months.
- Normally 80 to 90 percent of the follicles are in the anagen phase, less than 1 percent being in the catagen phase, and the rest being in the telogen phase. In the telogen phase, hair is uniform in diameter with a slightly bulbous, non-pigmented root. By contrast, in the anagen phase, hair has a large colored bulb at its root.
- “Promoting hair growth” refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
- “Treating alopecia” refers to:
- (i) preventing alopecia in an animal which may be predisposed to alopecia; and/or
- (ii) inhibiting, retarding or reducing alopecia; and/or
- (iii) promoting hair growth; and/or
- (iv) prolonging the anagen phase of the hair cycle; and/or
- (v) converting vellus hair to growth as terminal hair. Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep in the dermis. Vellus hair, on the other hand, is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type.
- The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative.
- The inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
- The present invention also relates to a pharmaceutical composition comprising:
- (i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal; and
- (ii) a pharmaceutically acceptable carrier.
- The pipecolic acid derivatives used in the methods and pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins, such as FKBP12. When a pipecolic acid derivative binds to an FKBP-type immunophilin, it has been found to inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein. Unexpectedly, the compounds have also been found to stimulate hair growth. These rotamase inhibiting compounds may be immunosuppressive or non-immunosuppressive. Examples of useful compounds are set forth below.
-
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- m is 0-3;
- A is CH2, O, NH, or N—(C1-C4 alkyl);
-
- wherein Q is hydrogen, C1-C6 straight or branched chain alkyl, or C2-C6 straight or branched chain alkenyl; and
- T is Ar or C5-C7 cycloalkyl substituted at
positions - Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatom(s) independently selected from the group consisting of oxygen, nitrogen and sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF3, trifluoromethoxy, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;
- L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;
- U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, (C1-C4 alkyl or C2-C4 alkenyl) —Ar, or Ar;
- J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2; and
- said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
- Representative species of Formula I are presented in Table I.
TABLE I Compound n m B D L 1 2 0 3-Phenyl- 3-(3-Pyridyl)- Phenyl propyl propyl 2 2 0 3-Phenyl- 3-(2-Pyridyl)- Phenyl propyl propyl 3 2 0 3-Phenyl- 2-(4-Methoxy- Phenyl propyl phenyl) ethyl 4 2 0 3-Phenyl- 3-Phenylpropyl Phenyl propyl 5 2 0 3-Phenyl- 3- Phenylpropyl 3,4,5- propyl Trimeth- oxyphenyl 6 2 0 3-Phenyl- 2-(3-Pyridyl)- 3,4,5- propyl propyl Trimeth- oxyphenyl 7 2 0 3-Phenyl- 3-(2-Pyridyl)- 3,4,5- propyl propyl Trimeth- oxyphenyl 8 2 0 3-Phenyl- 3-(4-Methoxy- 3,4,5- propyl phenyl)propyl Trimeth- oxyphenyl 9 2 0 3-Phenyl- 3-(3-Pyridyl)- 3-Iso- propyl propyl propoxy- phenyl -
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- A is O, NH, or N—(C1-C4 alkyl)
-
- wherein L and Q are independently hydrogen, C1-C6 straight or branched chain alkyl, or C2-C6 straight or branched chain alkenyl; and
- T is Ar or C5-C7 cyclohexyl substituted at
positions - Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF3, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.
- D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;
- U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7-cycloalkyl, C5-C7 cycloalkenyl substituted with C2-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C1-C4 alkyl or C2-C4 alkenyl)-Ar, or Ar;
- J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2.
-
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- n is 2;
- D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl; and
- B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl)butyl;
- provided that:
- when D is phenyl, then B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;
- when D is methoxy, B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;
- when D is 2-furyl, then B is benzyl; and
- when D is 3,4,5-trimethoxyphenyl, then B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3- (3-indolyl)propyl, or 4- (4 -methoxyphenyl)butyl.
- Representative species of Formula III are presented in Table II.
TABLE II III Compound B D n 10 Benzyl Phenyl 2 11 3- Phenylpropyl Phenyl 2 12 4-(4-Methoxyphenyl)- Phenyl 2 butyl 13 4- Phenylbutyl Phenyl 2 14 Phenethyl Phenyl 2 15 4- Cyclohexylbutyl Phenyl 2 16 Benzyl Methoxy 2 17 4- Cyclohexylbutyl Methoxy 2 18 3- Cyclohexylpropyl Methoxy 2 19 3- Cyclopentylpropyl Methoxy 2 20 Benzyl 2- Furyl 2 21 4- Cyclohexylbutyl 3,4,5- 2 Trimethoxyphenyl 22 3- Phenoxybenzyl 3,4,5- 2 Trimethoxyphenyl 23 4- Phenylbutyl 3,4,5- 2 Trimethoxyphenyl 24 3-(3-Indolyl)propyl 3,4,5- 2 Trimethoxyphenyl 25 4-(4-Methoxyphenyl)- 3,4,5- 2 butyl Trimethoxyphenyl -
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- V is C, N, or S;
- J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
- R is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C1-C9 cycloakyl, C5-C7 cycloalkenyl, or Ar1, wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar2;
- Ar1 and Ar2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;
- A, B, D, L, M, and m are as defined in Formula I above; and
- said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
- All the compounds of Formulas I-IV possess asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving the compounds of Formulas I-IV. It is understood that the compounds of Formulas I-IV encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers. Preferably, S-stereoisomers are used in the pharmaceutical compositions and methods of the present invention.
- The compounds used in the inventive methods and pharmaceutical compositions have an affinity for the FK506 binding protein, particularly FKBP12. The inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.
- Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the compounds used in the inventive methods and pharmaceutical compositions can be evaluated by known methods described in the literature (Harding et al.,Nature, 1989, 341:758-760; Holt et al. J. Am. Chem. Soc., 115:9923-9938). These values are obtained as apparent Ki's and are presented for representative compounds in TABLE III.
- The cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala—Ala—Pro—Phe- p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent Ki values.
- In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 mL of substrate (succinyl-Ala—Phe—Pro—Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).
- The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.
TABLE III In Vitro Test Results - Formulas I-III Compound Ki (μM) 10 1.5 13 0.35 14 1.1 15 0.4 16 80 17 6 18 20 19 35 20 3 21 0.04 22 0.018 23 0.019 24 0.017 25 0.013 - To effectively treat alopecia or promote hair growth, the compounds used in the inventive methods and pharmaceutical compositions must readily affect the targeted areas. For these purposes, the compounds are preferably administered topically to the skin.
- For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- Other routes of administration known in the pharmaceutical art are also contemplated by this invention.
- Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
- The compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the drug combination.
- The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition.
- Experiment A: C57 black 6 mice were used to demonstrate the hair revitalIzing properties of pipecolic acid derivative GPI1044 (compound 4), as well as related pipecolic acid derivative neuroimmunophilin FKBP ligands
GPI 1102 andGPI 1116. C57 black 6 mice, approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlaying dermal layers. The animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS. 1 and 2, four animals were treated by topical administration with 20% propylene glycol vehicle (FIG. 1), and seven animals were treated by topical administration with 10 μM GPI 1044 (FIG. 2). The animals were treated with vehicle orGPI 1044 every 48 hours (3 applications total over the course of 5 days) and the hair growth was allowed to proceed for 6 weeks. Hair growth was quantitated by the percent of shaved area covered by new hair growth during this time period. - FIG. 1 shows that animals treated with vehicle exhibited only a small amount of hair growth in patches or tufts, with less than 3% of the shaved area covered with new growth. In contrast, FIG. 2 shows that animals treated with 10
μM GPI 1044 exhibited dramatic hair growth, covering as much as 50% of the shaved area in some animals. FIG. 3 compares the hair growth score of unshaven animals with the hair growth scores of shaven animals treated with a vehicle and GPI 1044 (1 μM, 3 μM and 10 μM), as well as related neuroimmunophilin FKBP ligands GPI 1116 (1 μM and 10 μM) and GPI 1102 (1 μM and 3 μM). - Experiment B: C57 Black 6 mice were used to demonstrate the hair revitalizing properties of neuroimmunophilin FKBP ligands. C57 Black 6 mice, 55 to 75 days old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlying dermal layers. The animals were in a anagen growth phase when shaved. Five animals per group were treated by topical administration with a vehicle, FK506, or a neuroimmunophilin FKBP ligand (
GPI 1116 or 1206) at a concentration of one micromole per milliliter to the shaved area. The animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area). - FIG. 4 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with one of the low molecular weight, small molecule, neuroimmunophilin FKBP ligands exhibited dramatic hair growth.
- A lotion comprising the following composition may be prepared.
(%) 95% Ethanol 80.0 a pipecolic acid derivative as defined above 10.0 α-Tocopherol acetate 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s. - Into 95% ethanol are added a pipecolic acid derivative, α-tocopherol acetate, ethylene oxide (40 mole) adducts of hardened castor oil, perfume and a dye. The resulting mixture is stirred and dissolved, and purified water is added to the mixture to obtain a transparent liquid lotion.
- 5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
- A lotion comprising the following composition shown may be prepared.
(%) 95% Ethanol 80.0 a pipecolic acid derivative as defined above 0.005 Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil Purified water 19.0 Perfume and dye q.s. - Into 95% ethanol are added a pipecolic acid derivative, hinokitol, ethylene oxide (40 mole) adducts of hardened castor oil, perfume, and a dye. The resulting mixture is stirred, and purified water is added to the mixture to obtain a transparent liquid lotion.
- The lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
- An emulsion may be prepared from A phase and B phase having the following compositions.
(%) (A phase) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monooleate 1.0 a pipecolic acid derivative as defined above 0.01 (B phase) Glycerine 10.0 Purified water 69.0 Perfume, dye, and preservative q.s. - The A phase and the B phase are respectively heated and melted and maintained at 80° c. Both phases are then mixed and cooled under stirring to normal temperature to obtain an emulsion.
- The emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia.
- A cream may be prepared from A phase and B phase having the following compositions.
(%) (A Phase) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3 (B Phase) a pipecolic acid derivative as defined above 0.8 Glycerine 7.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0.005 Purified water 44.895 - The A phase is heated and melted, and maintained at 70° C. The B phase is added into the A phase and the mixture is stirred to obtain an emulsion. The emulsion is then cooled to obtain a cream.
- The cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
- A liquid comprising the following composition may be prepared.
(%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 a pipecolic acid derivative as defined above 0.001 Propylene glycol 5.0 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q.s. - Into ethanol are added polyoxypropylene butyl ether, propylene glycol, polyoxyethylene hardened castor oil, a pipecolic acid derivative, and perfume. The resulting mixture is stirred, and purified water is added to the mixture to obtain a liquid.
- The liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
- A shampoo comprising the following composition may be prepared.
(%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 Polyethylene glycol 5.0 a pipecolic acid derivative as defined above 5.0 Ethanol 2.0 Perfume 0.3 Purified water 69.7 - Into 69.7 of purified water are added 5.0 g of sodium laurylsulfate, 5.0 g of triethanolamine laurylsulfate, 6.0 g of betaine lauryldimethyl-aminoacetate. Then a mixture obtained by adding 5.0 g of a pipecolic acid derivative, 5.0 g of polyethylene glycol, and 2.0 g of ethylene glycol distearate to 2.0 g of ethanol, followed by stirring, and 0.3 g of perfume are successively added. The resulting mixture is heated and subsequently cooled to obtain a shampoo.
- The shampoo may be used on the scalp once or twice per day.
- A patient is suffering from alopecia senilis. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from male pattern alopecia. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from alopecia areata. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by skin lesions. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by tumors. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by a systematic disorder, such as a nutritional disorder or an internal secretion disorder. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by chemotherapy. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by radiation. A pipecolic acid derivative, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.
Claims (8)
1. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula I
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A is CH2, O, NH, or N—(C1-C4 alkyl);
B and D are independently Ar, C5-C7 cycloalkyl substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkenyl substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, or Ar substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO2 in chemically reasonable substitution patterns, or
wherein Q is hydrogen, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl; and
T is Ar or C5-C7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C1-C4 alkyl), O—(C2-C4 alkenyl), and carbonyl;
Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen ard sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF3, trifluoromethoxy, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C 4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;
L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;
U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, (C1-C4 alkyl or C2-C4 alkenyl) —Ar, or Ar;
J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2;
n is 0-3; and
said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
2. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula II
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A is O, NH, or N-(C1-C4 alkyl);
B is hydrogen, CHL-Ar, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl, Ar substituted C1-C6 alkyl or C2-C6 alkenyl, or
wherein L and Q are independently hydrogen, C1-C6 straight or branched chain alkyl, or C2-C6 straight or branched chain alkenyl; and
T is Ar or C5-C7 cyclohexyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C1-C4 alkyl), O—(C2-C4 alkenyl), and carbonyl;
Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF3, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.
D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;
U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7-cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C1-C4 alkyl or C2-C4 alkenyl) —Ar, or Ar;
J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2.
3. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula III
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
n is 2;
D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl; and
B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4- (4-methoxyphenyl)butyl;
provided that
when D is phenyl, then B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;
when D is methoxy, then B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;
when D is 2-furyl, then B is benzyl; and
when D is 3,4,5-trimethoxyphenyl, then B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl) butyl.
4. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a pipecolic acid derivative of formula IV
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
V is C, N, or S;
J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloakyl, C5-C7 cycloalkenyl, or Ar1, wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar2;
Ar1 and Ar2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;
A, B, D, L, M, and m are as defined in above; and
claim 1
said pipecolic acid derivative has an affinity for FKBP-type immunophilins.
5. A pharmaceutical composition which comprises:
(i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula I
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A is CH2, O, NH, or N—(C1-C4 alkyl);
B and D are independently Ar, C5-C7 cycloalkyl substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkenyl substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, or Ar substituted C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO2 in chemically reasonable substitution patterns, or
wherein Q is hydrogen, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl; and
T is Ar or C5-C7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C1-C4 alkyl), O—(C2-C4 alkenyl), and carbonyl;
Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms is independently selected from oxygen, nitrogen and sulfur; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF3, trifluoromethoxy, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl) , O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;
L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;
U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, (C1-C4 alkyl or C2-C4 alkenyl) —Ar, or Ar;
J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2;
n is 0-3; and
said pipecolic acid derivative has an affinity for FKBP-type immunophilins; and
(ii) a pharmaceutically acceptable carrier.
6. A pharmaceutical composition which comprises:
(i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula II
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A is O, NH, or N-(C1-C4 alkyl);
B is hydrogen, CHL-Ar, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl, Ar substituted C1-C6 alkyl or C2-C6 alkenyl, or
wherein L and Q are independently hydrogen, C1-C6 straight or branched chain alkyl, or C2-C6 straight or branched chain alkenyl; and
T is Ar or C5-C7 cyclohexyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O—(C1-C4 alkyl), O—(C2-C4 alkenyl), and carbonyl;
Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF3, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl.
D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;
U is hydrogen, O—(C1-C4 straight or branched chain alkyl), O—(C2-C4 straight or branched chain alkenyl), C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C5-C7 cycloalkyl, C5-C7 cycloalkenyl substituted with C1-C4 straight or branched chain alkyl or C2-C4 straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C1-C4 alkyl or C2-C4 alkenyl) —Ar, or Ar;
J is hydrogen, C1 or C2 alkyl, or benzyl; K is C1-C4 straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO2; and
(ii) a pharmaceutically acceptable carrier.
7. A pharmaceutical composition which comprises:
(i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula III
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
n is 2;
D is phenyl, methoxy, 2-furyl, or 3,4,5-trimethoxyphenyl; and
B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl) butyl, 4-phenylbutyl, phenethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 3-phenoxybenzyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl)butyl;
provided that
when D is phenyl, then B is benzyl, 3-phenylpropyl, 4-(4-methoxyphenyl)butyl, 4-phenylbutyl, phenethyl, or 4-cyclohexylbutyl;
when D is methoxy, then B is benzyl, 4-cyclohexylbutyl, 3-cyclohexylpropyl, or 3-cyclopentylpropyl;
when D is 2-furyl, then B is benzyl; and
when D is 3,4,5-trimethoxyphenyl, then B is 4-cyclohexylbutyl, 3-phenoxybenzyl, 4-phenylbutyl, 3-(3-indolyl)propyl, or 4-(4-methoxyphenyl) butyl; and
(ii) a pharmaceutically acceptable carrier.
8. A pharmaceutical composition which comprises:
(i) an effective amount of a pipecolic acid derivative for treating alopecia or promoting hair growth in an animal, wherein the pipecolic acid derivative is a compound of formula formula IV
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
V is C, N, or S;
J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloakyl, C5-C7 cycloalkenyl, or Ar1, wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar2;
Ar1 and Ar2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;
A, B, D, L, M, and m are as defined in above; and
claim 5
(ii) a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/784,174 US20010036952A1 (en) | 1997-06-04 | 2001-02-16 | Small molecule pipecolic acid derivative hair growth compositions and uses |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/869,426 US5945441A (en) | 1997-06-04 | 1997-06-04 | Pyrrolidine carboxylate hair revitalizing agents |
US09/089,373 US6191125B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule pipecolic acid derivative hair growth compositions and uses |
US09/784,174 US20010036952A1 (en) | 1997-06-04 | 2001-02-16 | Small molecule pipecolic acid derivative hair growth compositions and uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/089,373 Division US6191125B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule pipecolic acid derivative hair growth compositions and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010036952A1 true US20010036952A1 (en) | 2001-11-01 |
Family
ID=25353537
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/869,426 Expired - Fee Related US5945441A (en) | 1997-06-04 | 1997-06-04 | Pyrrolidine carboxylate hair revitalizing agents |
US09/089,373 Expired - Fee Related US6191125B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule pipecolic acid derivative hair growth compositions and uses |
US09/089,375 Expired - Fee Related US6004993A (en) | 1997-06-04 | 1998-06-03 | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses |
US09/089,832 Expired - Fee Related US6194440B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule carbamate or urea hair growth compositions and uses |
US09/089,415 Expired - Fee Related US6177455B1 (en) | 1997-06-04 | 1998-06-03 | Pyrrolidine derivative hair growth compositions and uses |
US09/359,709 Expired - Fee Related US6187806B1 (en) | 1997-06-04 | 1999-07-23 | N-linked sulfone of heterocyclic thioester hair growth compositions and uses |
US09/369,860 Expired - Fee Related US6239164B1 (en) | 1997-06-04 | 1999-08-09 | Pyrrolidine carboxylate and pyrrolidine amide hair revitalizing agents |
US09/784,174 Abandoned US20010036952A1 (en) | 1997-06-04 | 2001-02-16 | Small molecule pipecolic acid derivative hair growth compositions and uses |
US09/791,661 Abandoned US20020037924A1 (en) | 1997-06-04 | 2001-02-26 | Small molecule carbamate or urea hair growth compositions and uses |
US09/825,896 Abandoned US20010029263A1 (en) | 1997-06-04 | 2001-04-05 | Novel pyrrolidine carboxylate hair revitalizing agents |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/869,426 Expired - Fee Related US5945441A (en) | 1997-06-04 | 1997-06-04 | Pyrrolidine carboxylate hair revitalizing agents |
US09/089,373 Expired - Fee Related US6191125B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule pipecolic acid derivative hair growth compositions and uses |
US09/089,375 Expired - Fee Related US6004993A (en) | 1997-06-04 | 1998-06-03 | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses |
US09/089,832 Expired - Fee Related US6194440B1 (en) | 1997-06-04 | 1998-06-03 | Small molecule carbamate or urea hair growth compositions and uses |
US09/089,415 Expired - Fee Related US6177455B1 (en) | 1997-06-04 | 1998-06-03 | Pyrrolidine derivative hair growth compositions and uses |
US09/359,709 Expired - Fee Related US6187806B1 (en) | 1997-06-04 | 1999-07-23 | N-linked sulfone of heterocyclic thioester hair growth compositions and uses |
US09/369,860 Expired - Fee Related US6239164B1 (en) | 1997-06-04 | 1999-08-09 | Pyrrolidine carboxylate and pyrrolidine amide hair revitalizing agents |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/791,661 Abandoned US20020037924A1 (en) | 1997-06-04 | 2001-02-26 | Small molecule carbamate or urea hair growth compositions and uses |
US09/825,896 Abandoned US20010029263A1 (en) | 1997-06-04 | 2001-04-05 | Novel pyrrolidine carboxylate hair revitalizing agents |
Country Status (12)
Country | Link |
---|---|
US (10) | US5945441A (en) |
EP (3) | EP1479373B1 (en) |
JP (2) | JP2002510302A (en) |
AT (1) | ATE275930T1 (en) |
AU (2) | AU751057B2 (en) |
CA (2) | CA2292910C (en) |
DE (2) | DE69826267T2 (en) |
ES (1) | ES2229498T3 (en) |
MX (1) | MXPA99010886A (en) |
TW (3) | TW490307B (en) |
WO (2) | WO1998055091A1 (en) |
ZA (3) | ZA984621B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218424B1 (en) * | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US5846979A (en) * | 1997-02-28 | 1998-12-08 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic esters, amides, thioesters, and ketones |
US6274602B1 (en) * | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
EP1085853A1 (en) * | 1998-06-03 | 2001-03-28 | GPI NIL Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
EA008723B1 (en) * | 1998-06-03 | 2007-06-29 | Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. | Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
CN1295561A (en) * | 1998-06-03 | 2001-05-16 | Gpinil控股公司 | N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres |
EA200001144A1 (en) * | 1998-06-03 | 2001-10-22 | Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. | AZA-HETEROCYCLIC COMPOUNDS APPLIED TO THE TREATMENT OF NEUROLOGICAL DISORDERS AND HAIR LOSS |
US6429215B1 (en) | 1998-06-03 | 2002-08-06 | Gpi Nil Holdings, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US6506788B1 (en) * | 1998-08-14 | 2003-01-14 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
US6218423B1 (en) * | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US7410995B1 (en) * | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
US6337340B1 (en) * | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US7338976B1 (en) * | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
US6384056B1 (en) * | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
EP1117371A2 (en) * | 1998-09-30 | 2001-07-25 | The Procter & Gamble Company | Method of treating hair loss using ketoamides |
US6307049B1 (en) * | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
NZ516888A (en) * | 1999-07-30 | 2004-02-27 | Vertex Pharma | Acyclic and cyclic amine derivatives |
WO2001010837A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent sulfonamides |
AU6611800A (en) * | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Method of treating hair loss using multivalent ketoamides and amides |
AU6499000A (en) * | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Multivalent compounds |
WO2001010839A2 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent substituted ketoamides and amides for treating hair loss |
US6593362B2 (en) * | 2001-05-21 | 2003-07-15 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
US7169564B1 (en) * | 2001-06-26 | 2007-01-30 | Anaderm Research Corporation | FKBP51/52 and CyP40-mediated mammalian hair growth |
US7598278B2 (en) * | 2002-04-11 | 2009-10-06 | L'oreal | Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss |
AU2003257143A1 (en) * | 2002-07-31 | 2004-02-16 | Shaklee Corporation | A method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
US7476399B2 (en) | 2003-08-06 | 2009-01-13 | Senomyx Inc. | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
NZ550853A (en) * | 2004-04-28 | 2009-04-30 | Cosmo Oil Co Ltd | Hair restorer |
WO2006069038A1 (en) * | 2004-12-20 | 2006-06-29 | Ariad Gene Therapeutics, Inc. | Therapeutic materials and methods |
CN101610751B (en) * | 2006-12-20 | 2012-03-21 | 大正制药株式会社 | Prophylactic or therapeutic agent for alopecia |
US20080221115A1 (en) * | 2007-02-26 | 2008-09-11 | Liat Hayardeny-Nisimov | Use of long-chain alcohol derivatives for the treatment of alopecia areata |
TWI534142B (en) | 2011-03-15 | 2016-05-21 | 大正製藥股份有限公司 | Azole derivatives |
JP6020396B2 (en) * | 2012-09-12 | 2016-11-02 | 大正製薬株式会社 | Medicaments containing azole derivatives |
FR3030248B1 (en) | 2014-12-22 | 2018-03-23 | L'oreal | PYRIDINE-DICARBOXYLIC ACID DERIVATIVE ASSOCIATION / PARTICULAR ANTIOXIDANT AGENT |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2505114C3 (en) | 1975-02-07 | 1979-06-13 | Valentin Dr.Med. Koehler | Scalp care products |
US4070361A (en) | 1977-04-21 | 1978-01-24 | E. R. Squibb & Sons, Inc. | Mercaptoalkylsulfonyl proline and pipecolic acid and esters thereof |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4390695A (en) | 1980-06-23 | 1983-06-28 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4578474A (en) * | 1980-06-23 | 1986-03-25 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4310461A (en) | 1980-06-23 | 1982-01-12 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4950649A (en) | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
GR75019B (en) | 1980-09-17 | 1984-07-12 | Univ Miami | |
ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
DE3174844D1 (en) | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
ZA826022B (en) | 1981-08-21 | 1983-08-31 | Univ Miami | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides |
US4438031A (en) | 1982-02-24 | 1984-03-20 | American Home Products Corporation | N-(Alkylsulfonyl)-L-proline amide and N-(alkylsulfonyl)-2-carboxylic acid amide-indoline derivatives |
EP0088350B1 (en) | 1982-03-08 | 1985-02-20 | Schering Corporation | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
US4531964A (en) | 1982-09-13 | 1985-07-30 | Nippon Kayaku Kabushiki Kaisha | Heterocyclic compound and a herbicidal composition containing said compound |
US4574079A (en) | 1983-05-27 | 1986-03-04 | Gavras Haralambos P | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
US4593102A (en) | 1984-04-10 | 1986-06-03 | A. H. Robins Company, Inc. | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
DE3508251A1 (en) * | 1985-03-08 | 1986-09-11 | Merck Patent Gmbh, 6100 Darmstadt | Dipeptides |
CN86101850A (en) | 1985-03-22 | 1987-02-04 | 森得克斯(美国)有限公司 | N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides |
US5472687A (en) | 1985-07-18 | 1995-12-05 | Proctor; Peter H. | Topical pyridine N-oxides |
US5714510A (en) | 1985-07-18 | 1998-02-03 | Proctor; Peter H. | Topical proxyl composition and method |
WO1988000040A1 (en) | 1986-07-02 | 1988-01-14 | American Health Products Corporation | Topical hair growing composition and kit |
KR960004900B1 (en) | 1986-09-10 | 1996-04-17 | 신텍스(유.에스.에이.) 인코포레이티드 | Selective amidination of diamines |
GB8630721D0 (en) * | 1986-12-23 | 1987-02-04 | Unilever Plc | Cosmetic compositions |
IT1206078B (en) | 1987-06-03 | 1989-04-14 | Polifarma Spa | PROCEDURE FOR THE PRODUCTION OF 3-INDOLPIRUVIC ACID AND ITS DERIVATIVES THEIR PHARMACEUTICAL USE |
LU86959A1 (en) * | 1987-07-31 | 1989-03-08 | Oreal | NOVEL DERIVATIVES OF UREYLENE TRIAMINO-2,4,6 PYRIMIDINE OXIDE-3, THEIR PREPARATION AND THEIR USE IN COSMETICS AND DERMOPHARMACY |
WO1989006234A1 (en) | 1987-12-28 | 1989-07-13 | Bazzano Gail S | N,n-substituted amines and use thereof in hair growth promotion |
GB2216003B (en) * | 1988-02-18 | 1992-06-10 | Toyama Chemical Co Ltd | Hair restorer |
US5187156A (en) | 1988-03-16 | 1993-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same |
IL90872A0 (en) * | 1988-07-08 | 1990-02-09 | Smithkline Beckman Corp | Retroviral protease binding peptides |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
DE3931051A1 (en) | 1988-09-22 | 1990-03-29 | Hoechst Ag | New herbicidal amine salts of herbicidal acids |
EP0378318A1 (en) | 1989-01-11 | 1990-07-18 | Merck & Co. Inc. | Process for synthesis of FK-506 and tricarbonyl intermediates |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5359138A (en) | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
EP0672648B1 (en) * | 1989-04-15 | 1998-09-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Threo (2R,3S)-3-amino-2-hydroxypentanoic acid and threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentanoic acid |
US5164525A (en) | 1989-06-30 | 1992-11-17 | Merck & Co., Inc. | Synthetic process for fk-506 type macrolide intermediates |
US5284826A (en) * | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
NZ234883A (en) | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
FR2651122B1 (en) * | 1989-08-29 | 1994-10-28 | Oreal | COMPOSITIONS FOR USE IN BRAKING HAIR LOSS AND INDUCING AND STIMULATING THEIR GROWTH, CONTAINING 2-AMINO PYRIMIDINE OXIDE-3 DERIVATIVES AND NEW AMINO-2 PYRIMIDINE OXIDE-3 DERIVATIVES. |
GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
KR0159766B1 (en) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | Hair revitalizing agent |
IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
US5115098A (en) | 1990-02-28 | 1992-05-19 | President And Fellows Of Harvard College | End-blocked peptides inhibiting binding capacity of gp120 |
JPH04211648A (en) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | Keto-acid amide derivative |
DE4015255A1 (en) | 1990-05-12 | 1991-11-14 | Hoechst Ag | OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
ES2104597T3 (en) | 1990-08-14 | 1997-10-16 | Kenneth M Hallam | COMPOSITION FOR THE PROMOTION OF HAIR GROWTH. |
JPH06500561A (en) | 1990-08-24 | 1994-01-20 | ジ・アップジョン・カンパニー | Aminopolyol-containing peptides as transition state mimetics |
WO1992004370A1 (en) * | 1990-08-29 | 1992-03-19 | Vertex Pharmaceuticals Incorporated | Modified di- and tripeptidyl immunosuppressive compounds |
GB2247456A (en) * | 1990-09-03 | 1992-03-04 | Fujisawa Pharmaceutical Co | Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same |
JPH04149166A (en) * | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | Novel keto acid amide derivative |
FR2671082B1 (en) | 1990-12-28 | 1993-04-16 | Oreal | MULTI-COMPONENT AGENT OR KIT FOR PREPARING THE SULFO-CONJUGATED FORM OF PYRIMIDINO- OR TRIAZINO-N-OXIDE COMPOUNDS AND METHOD FOR IMPLEMENTING SAME. |
WO1992016501A1 (en) | 1991-03-20 | 1992-10-01 | Vertex Pharmaceuticals Incorporated | Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease |
IT1245712B (en) | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION |
US5147877A (en) | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
WO1992019745A1 (en) | 1991-05-08 | 1992-11-12 | Vertex Pharmaceuticals Incorporated | Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein |
US5620971A (en) | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
KR100244372B1 (en) * | 1991-05-09 | 2000-03-02 | 조슈아 에스.보저 | Novel immunosuppressive compounds |
US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
MX9202466A (en) * | 1991-05-24 | 1994-06-30 | Vertex Pharma | NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS. |
FR2677884B1 (en) | 1991-06-20 | 1993-07-09 | Oreal | COMPOSITION FOR BRAKING HAIR LOSS BASED ON TRISUBSTITUTED N-OXIDE PYRIMIDINES OR THEIR SULFOCONJUGAL DERIVATIVES, NOVEL PYRIMIDINE N-OXIDE COMPOUNDS OR THEIR SULFOCONJUGAL DERIVATIVES. |
JPH05178824A (en) | 1991-08-05 | 1993-07-20 | Takeda Chem Ind Ltd | Asparagine derivative and its use |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5457111A (en) * | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
AU2803692A (en) | 1991-10-11 | 1993-05-03 | Vertex Pharmaceuticals Incorporated | Isolation of an mr 52,000 fk506 binding protein and molecular cloning of a corresponding human cdna |
IL103394A0 (en) * | 1991-10-11 | 1993-03-15 | Ciba Geigy | Pyrimidinyl and triazinyl ethers and thioethers,their preparation and their use as herbicides |
AU3278293A (en) * | 1991-12-20 | 1993-07-28 | Syntex (U.S.A.) Inc. | Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors |
GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
AU3477093A (en) * | 1992-01-27 | 1993-09-01 | Merck & Co., Inc. | 17beta -hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones useful to treat baldness |
WO1993018736A1 (en) | 1992-03-19 | 1993-09-30 | Armand Pardo | Cosmetic hair care compositions for treating hair loss |
CA2091194A1 (en) * | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
WO1993023548A2 (en) * | 1992-05-20 | 1993-11-25 | Vertex Pharmaceuticals Incorporated | METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF |
IT1254373B (en) | 1992-05-29 | 1995-09-14 | HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR EMPLOYE THERAPEUTIC. | |
US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
US5284840A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkylidene macrolides having immunosuppressive activity |
US5334719A (en) * | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
GB9216329D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
NZ314207A (en) | 1992-09-28 | 2000-12-22 | Vertex Pharma | 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
AU5748194A (en) * | 1992-12-11 | 1994-07-04 | Vertex Pharmaceuticals Incorporated | Mannitol derivatives and their use as inhibitors of aspartyl protease |
DE4302860A1 (en) * | 1993-01-22 | 1994-08-04 | Chemie Linz Deutschland | N-Cyclic and N, N'dicyclic ureas |
US5385918A (en) * | 1993-02-09 | 1995-01-31 | Miles Inc. | Aminomethylene-peptides as immunosuppressants |
US5252579A (en) | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
US5631017A (en) | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
US5837703A (en) * | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
US5319098A (en) | 1993-05-18 | 1994-06-07 | Celgene Corporation | Process for the stereoselective preparation of L-alanyl-L-proline |
CA2167282A1 (en) * | 1993-07-16 | 1995-01-26 | Gerald R. Crabtree | Regulated apoptosis |
US5482284A (en) | 1993-08-09 | 1996-01-09 | Vandever; Claude S. | Golf address and stance teaching and practice device |
IT1270882B (en) | 1993-10-05 | 1997-05-13 | Isagro Srl | FUNGICIDE-BASED OLIGOPEPTIDES |
ES2130452T3 (en) | 1993-11-04 | 1999-07-01 | Abbott Lab | CYCLOBUTANE DERIVATIVES USED AS INHIBITORS OF SQUALENE-SYNTHESASE AND PROTEIN FARNESYL TRANSFERASE. |
JPH09504553A (en) | 1993-11-04 | 1997-05-06 | メルク エンド カンパニー インコーポレーテッド | 7-Substituted-4-aza-steroid derivatives as 5α-reductase inhibitors |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
CN1146201A (en) | 1994-03-07 | 1997-03-26 | 沃泰克斯药物股份有限公司 | Sulphonamide derivatives as aspartyl protease inhibitors |
US5744485A (en) | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
US5488816A (en) | 1994-07-21 | 1996-02-06 | Boehringer Mannheim Corporation | Method and apparatus for manufacturing a coagulation assay device in a continuous manner |
US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
US5506228A (en) * | 1995-02-23 | 1996-04-09 | Merck & Co., Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
US5574011A (en) * | 1995-04-04 | 1996-11-12 | Tien; Henry C. | Compositions and methods for the treatment of male-pattern baldness |
US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5726184A (en) | 1995-05-19 | 1998-03-10 | Vertex Pharmaceuticals Incorporated | Tetralin compounds with improved MDR activity |
US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US6037370A (en) * | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
WO1997031898A1 (en) * | 1996-02-28 | 1997-09-04 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
US5717092A (en) * | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
EP0823419A3 (en) | 1996-08-09 | 2000-08-16 | Takeda Chemical Industries, Ltd. | Dimethylpropanediol compounds |
US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
PT944645E (en) | 1996-12-06 | 2005-06-30 | Vertex Pharma | INHIBITORS OF INTERLEUCINA CONVERTER ENZYME 1BETA |
US5874449A (en) * | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
NZ335480A (en) * | 1996-12-31 | 2001-04-27 | Guilford Pharm Inc | Neurotrophic low molecular weight N-linked sulfonamides of heterocyclic thioesters and their use as inhibitors of immunophilin proteins |
US6271244B1 (en) * | 1998-06-03 | 2001-08-07 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
US6187784B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6187796B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6218423B1 (en) * | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
-
1997
- 1997-06-04 US US08/869,426 patent/US5945441A/en not_active Expired - Fee Related
-
1998
- 1998-05-29 ZA ZA984621A patent/ZA984621B/en unknown
- 1998-06-03 WO PCT/US1998/011246 patent/WO1998055091A1/en not_active Application Discontinuation
- 1998-06-03 DE DE69826267T patent/DE69826267T2/en not_active Expired - Fee Related
- 1998-06-03 TW TW087108779A patent/TW490307B/en active
- 1998-06-03 WO PCT/US1998/011237 patent/WO1998055090A1/en active IP Right Grant
- 1998-06-03 US US09/089,373 patent/US6191125B1/en not_active Expired - Fee Related
- 1998-06-03 TW TW087108774A patent/TW501931B/en not_active IP Right Cessation
- 1998-06-03 EP EP04020436A patent/EP1479373B1/en not_active Expired - Lifetime
- 1998-06-03 TW TW087108775A patent/TW518220B/en not_active IP Right Cessation
- 1998-06-03 JP JP50273499A patent/JP2002510302A/en active Pending
- 1998-06-03 US US09/089,375 patent/US6004993A/en not_active Expired - Fee Related
- 1998-06-03 CA CA002292910A patent/CA2292910C/en not_active Expired - Fee Related
- 1998-06-03 US US09/089,832 patent/US6194440B1/en not_active Expired - Fee Related
- 1998-06-03 AT AT98925148T patent/ATE275930T1/en not_active IP Right Cessation
- 1998-06-03 ZA ZA984783A patent/ZA984783B/en unknown
- 1998-06-03 CA CA002292965A patent/CA2292965C/en not_active Expired - Fee Related
- 1998-06-03 EP EP98925154A patent/EP0998263A1/en not_active Withdrawn
- 1998-06-03 US US09/089,415 patent/US6177455B1/en not_active Expired - Fee Related
- 1998-06-03 JP JP50273199A patent/JP4068164B2/en not_active Expired - Fee Related
- 1998-06-03 ES ES98925148T patent/ES2229498T3/en not_active Expired - Lifetime
- 1998-06-03 ZA ZA984778A patent/ZA984778B/en unknown
- 1998-06-03 EP EP98925148A patent/EP0983054B1/en not_active Expired - Lifetime
- 1998-06-03 DE DE69836878T patent/DE69836878D1/en not_active Expired - Lifetime
- 1998-06-03 AU AU77164/98A patent/AU751057B2/en not_active Ceased
- 1998-06-03 MX MXPA99010886A patent/MXPA99010886A/en not_active IP Right Cessation
- 1998-06-03 AU AU77169/98A patent/AU7716998A/en not_active Abandoned
-
1999
- 1999-07-23 US US09/359,709 patent/US6187806B1/en not_active Expired - Fee Related
- 1999-08-09 US US09/369,860 patent/US6239164B1/en not_active Expired - Fee Related
-
2001
- 2001-02-16 US US09/784,174 patent/US20010036952A1/en not_active Abandoned
- 2001-02-26 US US09/791,661 patent/US20020037924A1/en not_active Abandoned
- 2001-04-05 US US09/825,896 patent/US20010029263A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
US6943187B2 (en) | 1997-06-04 | 2005-09-13 | Gpi Nil Holdings, Inc. | Pyrrolidine derivative hair growth compositions and uses |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6191125B1 (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
US6274617B1 (en) | Heterocyclic ester and amide hair growth compositions and uses | |
US6187784B1 (en) | Pipecolic acid derivative hair growth compositions and uses | |
AU764032B2 (en) | Small molecule carbamate or urea hair growth compositions and uses | |
US6172087B1 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
AU760663B2 (en) | Small molecule sulfonamide hair growth compositions and uses | |
AU761737B2 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
EP1083874B1 (en) | Use of a compound for the preparation of a medicament for treating alopecia or promoting hair growth in an animal | |
US6187796B1 (en) | Sulfone hair growth compositions and uses | |
AU761083B2 (en) | Pipecolic acid derivative hair growth compositions and uses | |
US6271244B1 (en) | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses | |
US6274602B1 (en) | Heterocyclic thioester and ketone hair growth compositions and uses | |
US20020010205A1 (en) | N-linked sulfone of heterocyclic thioester hair growth compositions and uses | |
EP1083873B1 (en) | Heterocyclic thioester and ketone hair growth compositions and uses | |
MXPA00011850A (en) | Small molecule pipecolic acid derivative hair growth compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GLIAMED, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GPI IP, LLC, D/B/A MGL PHARMA;REEL/FRAME:019477/0568 Effective date: 20070405 |